Skip to main navigation

Our Company Pipeline Science Clinical Trials Investors & Media Careers

Our Company Pipeline Science Clinical Trials Investors & Media Careers

Investor Relations

Investor Relations
News Releases
Events, Presentations & Publications
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
SEC Filings
Annual Reports & Proxy Statements
Investor Resources

News Releases

Keyword Search

Year

Date	Title
May 18, 2017	Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6

Tools

Print Page
RSS Feeds
E-mail Alerts

(617) 995-0900 info@aileronrx.com

Hours

Mon

Tue

Wed

Thu

Fri

Sat

Sun

Our Company About Us Management Team Board of Directors

Pipeline ALRN-6924 Pipeline

Science Cell-Permeating Peptide Platform Targeting P53 Preclinical Research Scientific Publications

Clinical Trials

Investors & Media

Investor

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
Annual Reports & Proxy Statements
Investor Resources

Careers Join Our Team

Aileron Therapeutics, Inc.
490 Arsenal Way
Watertown, MA 02472

Phone: 617-995-0900
Fax: 617-995-2410
info@aileronrx.com